Related Experiment Video
Updated: Mar 3, 2026
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation
Yuanyuan Jin1, Linhu Li1, Zhaoyong Yang1
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Abstract:
Farnesyltransferase has been regarded as a promising drug target against cancer as it is critical for membrane association of several signal transduction proteins. In this study, a novel farnesyltransferase inhibitor (IMB-1406) was identified through virtual screening. It exhibits stronger potency (IC50s: 6.92-8.99 μM) than Sunitinib against all of the tested cancer cell lines. Preliminary studies on mechanism reveal that IMB-1406 induces apoptosis in HepG2 cells by arresting the cell cycle at the S phase, altering anti- and pro-apoptotic proteins leading to mitochondrial dysfunction and activation of caspase-3. This anti-tumor effect is most probably related to the inhibition of farnesyltransferase as indicated by molecular docking. Overall, IMB-1406 is a novel lead compound with potent antitumor activity and deserves further structural modifications.
Insights
A new compound, IMB-1406, shows potent anticancer activity by inhibiting farnesyltransferase, leading to cancer cell death. This novel inhibitor is more effective than Sunitinib in preliminary tests.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Farnesyltransferase is a key enzyme in cancer progression.
- Inhibiting farnesyltransferase is a promising anticancer strategy.
- Signal transduction proteins require membrane association mediated by farnesyltransferase.
Purpose of the Study:
- To identify novel farnesyltransferase inhibitors.
- To evaluate the anticancer potential of a new compound, IMB-1406.
- To elucidate the mechanism of action of IMB-1406.
Main Methods:
- Virtual screening to identify potential inhibitors.
- In vitro assays to determine inhibitory potency (IC50).
- Cell-based assays to assess apoptosis, cell cycle arrest, and mitochondrial function.
- Molecular docking to confirm target engagement.
Main Results:
- A novel farnesyltransferase inhibitor, IMB-1406, was identified.
- IMB-1406 demonstrated superior potency compared to Sunitinib across tested cancer cell lines.
- IMB-1406 induced apoptosis in HepG2 cells via S-phase cell cycle arrest, mitochondrial dysfunction, and caspase-3 activation.
Conclusions:
- IMB-1406 is a potent novel lead compound with significant antitumor activity.
- The observed anti-tumor effects are likely mediated by farnesyltransferase inhibition.
- IMB-1406 warrants further investigation and structural optimization for cancer therapy.
